Business context and reporting period
The supplied filing is ADVENTRX Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2011, filed March 8, 2012. This does not match the request metadata naming Savara Inc.; verify the issuer before relying on this summary. The filing is annual, not a standalone fourth-quarter report. ADVENTRX was a development-stage biopharmaceutical company with no product sales and no significant recurring revenue. Its lead candidate was ANX-188, acquired with SynthRx in April 2011; it also pursued ANX-514.
Financial and operating performance
| Metric | 2011 | 2010 |
|---|---|---|
| Revenue | $0 | $488,959, all from government grants |
| Operating expenses | $13.4 million | $9.0 million |
| Operating loss | $13.4 million | $8.5 million |
| Net loss | $13.3 million | $8.5 million |
| Net loss applicable to common stock | $13.3 million; $0.47 per share | $14.1 million; $1.07 per share |
| Research and development expense | $5.8 million | $3.7 million |
| Selling, general and administrative expense | $7.2 million | $5.0 million |
| Cash used in operating activities | $13.5 million | $8.3 million |
At year-end, cash and cash equivalents were $43.6 million, short-term investments $7.1 million, total current assets $51.8 million, current liabilities $2.5 million, and working capital $49.3 million. Total assets were $61.9 million and stockholders’ equity $56.8 million. The balance sheet reports no borrowings; total liabilities were $5.1 million, including a $2.6 million deferred tax liability. No product gross margin was generated in 2011. Q4 2011 revenue was zero and net loss was $2.4 million.
Changes versus the prior comparable period
- Operating expenses increased 48% to $13.4 million, driven primarily by higher R&D and SG&A spending, including ANX-188 development, added personnel, and Exelbine commercial-readiness work.
- R&D expense rose 56% to $5.8 million; management expected it to increase significantly in 2012 as ANX-188 studies advanced.
- Operating cash use increased by $5.1 million. Investing cash use rose to $7.5 million, mainly due to purchases of certificates of deposit; financing provided $36.6 million.
- Net loss applicable to common stock improved from $14.1 million to $13.3 million, largely because 2010 included $5.6 million of non-cash deemed preferred-stock dividends; 2011 operating loss itself worsened.
- Cash, cash equivalents and short-term investments increased from $28.0 million to $50.7 million, primarily following $36.6 million net proceeds from equity offerings.
Outlook, risks and unusual items
- Management expected year-end liquidity to fund the currently planned operating level for at least 12 months, but stated that additional financing would be needed to support its business plan. It anticipated significant and increasing losses for several years.
- Management planned to initiate an ANX-188 Phase 3 study for sickle-cell complications in 2012, alongside smaller studies, including a pilot Phase 2 study. Trial design and manufacturing preparation remained in progress; timing and costs were uncertain.
- ANX-514’s planned pivotal 400-patient study was not expected to start in 2012. The company was assessing devices or methods to measure fluid retention more objectively and could discontinue the program if expected costs were not financially justified.
- The FDA issued a complete response letter for Exelbine in August 2011, requiring a repeat bioequivalence study because the authenticity of study drugs could not be verified. ADVENTRX stopped independent development and sought a partner or investor.
- The SynthRx acquisition involved up to 13.5 million additional shares tied to ANX-188 milestones, creating potential dilution. The company raised $36.6 million net through 2011 equity offerings and had substantial outstanding warrants.
- Key risks include dependence on a small number of candidates, clinical and regulatory failure or delay, financing needs, single-source manufacturers, competition, reimbursement uncertainty, dilution, and NYSE Amex listing compliance. The company reported no material pending litigation and stated that internal control over financial reporting was effective; the financial statements received unqualified audit opinions.
Important facts for investors to verify
- Confirm the issuer: the filing is for ADVENTRX Pharmaceuticals, Inc., not Savara Inc.
- Review subsequent disclosures for ANX-188 trial initiation, protocol and FDA feedback, and actual development spending.
- Check the company’s subsequent cash runway, financing activity, warrant exercises, and share-count changes against the 2011 year-end figures.
- Assess whether ANX-514 continued development and whether Exelbine obtained a partner or resumed development.
- Examine the terms and potential share impact of SynthRx milestone consideration, and the company’s ability to maintain exchange listing and obtain future funding.